Jazz Pharmaceuticals
JAZZ
Performance
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company focused on identifying, developing, and commercializing medicines that address unmet medical needs. The company highlights its portfolio of medicines such as Epidiolex, Xyrem, Xywav, Defitelio, Rylaze, Vyxeos, and Zepzelca, and emphasizes commitment to improving patients’ lives across international markets. Its operations span research, development, and commercialization of therapies in areas including neurology, oncology, and rare diseases, with an emphasis on delivering meaningful clinical impact for patients worldwide.
Recent News
Omeros Corp (OMER) Q1 2026 Earnings Call Transcript
SEC Settles Insider-Trading Case Tied to Chimerix-Jazz Deal Due Diligence
Jazz Pharma’s Ziihera Combos Get FDA Priority Review for First‑line HER2‑positive Gastric Cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
Stock Market Today: Nasdaq, S&P 500 Mark New Highs; These Truck Stocks Clear Entries (Live Coverage)
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
DUET Trial: Low-Sodium Oxybate Significantly Consolidates Nighttime Sleep Architecture in Narcolepsy
FDA Seeks Permanent Future for Rare Pediatric Priority Review Vouchers
Jazz Pharmaceuticals PLC (JAZZ) Q1 2026 Earnings Call Transcript
ConcertAI Introduces Cadence Suite, Delivering Industry Leading Visibility and Predictive Insights Into the Patient’s Journey for Commercial Teams
UBS Lifts Jazz Pharma Price Target to $307, Upgrades to Buy
Takeda, Iambic Partner in Latest Pharma AI Push
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
2025 Novel Small Molecule FDA Drug Approvals
The Top 12 Companies Hiring in Biopharma Now
Recent Deals
No recent deals for this company.